Streetbeat News

Regulatory

STTK

Shattuck Labs will present complete dose-escalation data from its Phase 1A monotherapy clinical trial of SL-172154 in platinum-resistant ovarian cancer at the 2023 ASCO Meeting. SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:17 pm

REGN

Regeneron reports updated data from two Phase 2 expansion dose cohorts evaluating investigational linvoseltamab (formerly REGN5458) in patients with heavily pre-treated, relapsed/refractory multiple myeloma. The treatment demonstrated impressive efficacy at the recommended 200 mg dose in the LINKER-MM1 trial.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:14 pm

TERN

Terns Pharmaceuticals announced the publication of a trial-in-progress abstract for TERN-701, an allosteric BCR-ABL, for the 2023 ASCO Meeting. The China Phase 1 trial has completed enrollment of Cohort 5 in the Dose Escalation phase.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:12 pm

IMAB

I-Mab reports positive Phase 1b/2 study results for uliledlimab and toripalimab combination therapy in advanced NSCLC patients at ASCO 2023. A biomarker-guided pivotal trial is being planned.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:11 pm

TCRT

Alaunos Therapeutics will present early data from its Phase 1/2 trial of TCR-T cell therapy at the 2023 ASCO Meeting. The therapy targets TP53 and KRAS driver mutations in solid tumors and has shown a manageable safety profile. The non-viral Sleeping Beauty cell engineering platform has demonstrated proof-of-concept in manufacturing TCR-T cell therapies.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:10 pm

XLO

Xilio Therapeutics announced preliminary clinical data from its Phase 1 trial of XTX101, a potential cancer treatment. The results showed promising safety and tolerability profiles.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:09 pm

THRX

Theseus Pharmaceuticals reports initial dose escalation data from its ongoing Phase 1/2 trial of THE-630 in patients with advanced GIST, showing an encouraging safety profile and evidence of clinical activity in heavily pre-treated patients.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:09 pm

RLAY

Relay Therapeutics announced complete first-in-human dose escalation data for RLY-4008, an investigational FGFR2 inhibitor. The data from the Phase 1/2 ReFocus study in patients with FGFR2-altered cholangiocarcinoma and other solid tumors will be presented at the 2023 ASCO Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:06 pm

MOLN

Molecular Partners will present data from its ongoing Phase 1 trial of MP0317 monotherapy for patients with advanced solid tumors at the 2023 ASCO Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 9:04 pm